💰 Financial Record

This document is page 33 of a confidential investment memorandum for a fund named 'New Leaf' (likely New Leaf Venture Partners). It details the fund's strategy regarding late-stage commercialization and small-cap public biotech companies, citing specific successful exits like Acadia Pharmaceuticals (2.5x) and InterCept Pharmaceuticals (3.2x), as well as a recapitalization of MEI Pharma. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was obtained during a congressional investigation, likely into financial networks connected to the broader Epstein inquiry.